These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1725238)

  • 21. Specificity of antibodies produced against native or desialylated human immunodeficiency virus type 1 recombinant gp160.
    Benjouad A; Gluckman JC; Montagnier L; Bahraoui E
    J Virol; 1993 Mar; 67(3):1693-7. PubMed ID: 7679751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The envelope of HIV-1 as a key component to infectivity.
    Buchbinder A
    Prog AIDS Pathol; 1990; 2():1-11. PubMed ID: 2103853
    [No Abstract]   [Full Text] [Related]  

  • 23. Establishment and characterization of human immunodeficiency virus type 1 (HIV-1) envelope-specific CD4+ T lymphocyte lines from HIV-1-seropositive patients.
    Ratto S; Sitz KV; Scherer AM; Manca F; Loomis LD; Cox JH; Redfield RR; Birx DL
    J Infect Dis; 1995 Jun; 171(6):1420-30. PubMed ID: 7769275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD4+ T-lymphocyte lines developed from HIV-1-seropositive patients recognize different epitopes within the V3 loop.
    Ratto S; Sitz KV; Scherer AM; Loomis LD; Cox JH; Redfield RR; Birx DL
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Feb; 11(2):128-36. PubMed ID: 8556394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-1 neutralizing antibody and approaches to the envelope diversity problem.
    Matthews TJ; Langlois AJ; Butto S; Bolognesi D; Javaherian K
    Adv Exp Med Biol; 1991; 303():23-6. PubMed ID: 1725234
    [No Abstract]   [Full Text] [Related]  

  • 26. Immunogenic and antigenic properties of an HIV-1 gp120-derived multiple chain peptide.
    Kelker HC; Schlesinger D; Valentine FT
    J Immunol; 1994 Apr; 152(8):4139-48. PubMed ID: 8144976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Solution conformation of an immunogenic peptide derived from the principal neutralizing determinant of the HIV-2 envelope glycoprotein gp125.
    Campbell AP; Sykes BD; Norrby E; Assa-Munt N; Dyson HJ
    Fold Des; 1996; 1(2):157-65. PubMed ID: 9079375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potentially negative effects of AIDS vaccines based on recombinant viruses carrying HIV-1 derived envelope gene. A warning on AIDS vaccine development.
    Veljkovic V; Metlas R
    Vaccine; 1993; 11(3):291-2. PubMed ID: 8447156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens.
    Schirmbeck R; Deml L; Melber K; Wolf H; Wagner R; Reimann J
    Vaccine; 1995 Jun; 13(9):857-65. PubMed ID: 7483809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV-1 env, nef, and gag-specific T-cell immunity in mice: conserved epitopes in nef p27 and gag p25 proteins.
    Michel F; Hoffenbach A; Froussard P; Langlade-Demoyen P; Kaczorek M; Kieny MP; Plata F
    AIDS Res Hum Retroviruses; 1992 Apr; 8(4):469-78. PubMed ID: 1376136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Berman PW; Gregory TJ; Riddle L; Nakamura GR; Champe MA; Porter JP; Wurm FM; Hershberg RD; Cobb EK; Eichberg JW
    Nature; 1990 Jun; 345(6276):622-5. PubMed ID: 2190095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein.
    Gao F; Weaver EA; Lu Z; Li Y; Liao HX; Ma B; Alam SM; Scearce RM; Sutherland LL; Yu JS; Decker JM; Shaw GM; Montefiori DC; Korber BT; Hahn BH; Haynes BF
    J Virol; 2005 Jan; 79(2):1154-63. PubMed ID: 15613343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Which gp160 vaccine?
    Moore J; Lewis GK; Robinson J
    Nature; 1993 Feb; 361(6412):503. PubMed ID: 7679205
    [No Abstract]   [Full Text] [Related]  

  • 34. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fine specificity of the humoral immune response to HIV-1 GP160 in HIV-1 infected individuals from Tanzania.
    Nkya WM; Warren RQ; Wolf H; Hendrix CW; Tesha J; Redfield RR; Melcher GP; Burke DS; Kanda P; Kennedy RC
    J Med Virol; 1992 May; 37(1):61-6. PubMed ID: 1619399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunological analysis of human immunodeficiency virus type 1 envelope glycoprotein proteolytic cleavage.
    Fenouillet E; Gluckman JC
    Virology; 1992 Apr; 187(2):825-8. PubMed ID: 1372142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of antibody reactivity to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in sera from HIV-1-infected individuals from Tanzania and from the United States.
    Warren RQ; Nkya WM; Shao JF; Anderson SA; Wolf H; Hendrix CW; Kanda P; Wabuke M; Boswell RN; Redfield RR
    J Clin Microbiol; 1992 Jan; 30(1):126-31. PubMed ID: 1370844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
    Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
    J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of neutralizing sites in the second variable and fourth variable region in gp125 and a conserved region in gp36 of human immunodeficiency virus type 2.
    Skott P; Achour A; Norin M; Thorstensson R; Björling E
    Viral Immunol; 1999; 12(1):79-88. PubMed ID: 10333245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers.
    Pincus SH; Messer KG; Nara PL; Blattner WA; Colclough G; Reitz M
    J Clin Invest; 1994 Jun; 93(6):2505-13. PubMed ID: 7515393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.